Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: April 19, 2006
Last updated: February 4, 2013
Last verified: January 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)